natgillin/translations-raw huggingface dataset:
The compound according to claim 9 or a pharmacologically acceptable salt thereof, wherein in the formula (I), Ar1 is a group selected from the group consisting of B1), B2), B6b), B9c), and B9d): wherein R1 is a hydrogen atom, a hydroxy group, a C1 to C3 alkyl group, a C1 to C3 alkoxy group, or a hydroxy C1 to C4 alkyl group; 
Spoj u skladu sa patentnim zahtjevom 9 ili njegova farmakološki prihvatljiva sol, ili njegov solvat ili hidrat, gdje u formuli (I), Ar1 je grupa odabrana iz grupe koja se sastoji od B1), B2), B6b), B9c), i B9d): [image] gdje R1 je atom vodika, hidroksi grupa, C1 do C3 alkil grupa, C1 do C3 alkoksi grupa, ili hidroksi C1 do C4 alkil grupa;
Flexible conduit according to claim 1, wherein the one or more indentations near the outer circumference of the ring. 
Fleksibilni cjevovod sukladno prethodnom zahtjevu, pri čemu se udubljenje pruža u blizini vanjske cirkumferencije prstena.
The automated packing machine will typically be of the type called Ilsemann KVD-30, Kyoto DVD100 and GIMA DVD872. 
Automatizirani stroj za pakiranje će tipično biti one vrste kao što je Ilsemann KVD-30, Kyoto DVD100 i GIMA DVD872.
The pharmaceutical composition according to claim 31, wherein said composition is provided in a dosage form which is a gel or inside a capsule shell. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 24, naznačen time što navedeni pripravak dolazi u obliku doziranja koji je gel ili unutar ljuske kapsule.
The mixing of excipients or of excipients with donepezil hydrochloride may be effected in conventional devices used for mixing of powders, e.g. motionless (passive) mixers, fluidized bed, diffusion, biconic diffusion, biconic, turbula, cubic, planetary, Y-, V-shaped or high-shear mixers. 
Miješanje samog ekscipijensa ili ekscipijensa sa donepezil hidrokloridom može se provesti u uobičajenim uređajima koji se koriste za miješanje prašaka, na primjer pasivnim mikserima, fluidnim ležištem, difuzijom, bikoničnom difuzijom, turbulencijom, kubičnim mikserima, planeternim mikserima, mikserima oblika Y ili V, mikserima za sjeckanje.
The method according to any of the preceding claims, further comprising attaching the raw paper (2) to the powder based sublayer (12). 
Metoda u skladu sa patentnim zahtjevima 2 ili 3, gdje je papir (2) tanak sirov papir sa težinom od oko 40 - 60 2/m2.
The method according to claim 24, wherein Rb3 and Rb5 are independently selected from hydrogen, methyl, C1-C6 alkyl substituted with heterocyclyl, and unsubstituted C1-C6 alkoxy wherein Rb2 and Rb3 and/or Rb5 and Rb6 may be connected to form a phenyl ring. 
Farmaceutski sastav za uporabu prema zahtjevu 2, naznačen time, da su Rb; i Rbs neovisno odabrani od sljedećih: vodik, metil, C,-Cg alkil supstituiran s heterociklom, i nesupstituirani C,-Cg alkoksi, gdje Rb2i Rbs i/ili Rbs i Rb; mogu biti spojeni za tvorbu fenilnog prstena.
The cell of claim 1, wherein the nucleic acid comprises the nucleic acid sequence of SEQ ID NO: 8. 
(v1) CAR je kodiran sekvencom nukleinske kiseline naznačenom u sekvenci SEQ ID NO:8.
The most preferred carbonaceous fuel elements used in practicing the invention are substantially free of volatile inorganic material. 
Najpoželjniji ugljični gorivi element koji se koristi u prakticiranju izuma su suštinski slobodni od isparljivog organskog materijala.
A bone targeted alkaline phosphatase comprising a polypeptide having the structure: Z-sALP-Y-spacer-X-Wn-V, wherein sALP is the extracellular domain of the alkaline phosphatase; wherein V is absent or is an amino acid sequence of at least one amino acid; 
Alkalna fosfataza usmjerena na kosti koja sadrži polipeptid koji ima slijedeću strukturu: Z-SsALP- Y-razmak-X-Wn-V, naznačena time da sALP je izvanstanična domena alkalne fosfataze; pri čemu V je odsutan ili je aminokiselinski slijed sa barem jednom aminokiselinom;
the nucleic acid sequence set forth in SEQ ID NO: 1; and ii) a nucleic acid sequence coding for a sub-sequence or analogue of the sequence set forth in SEQ ID NO 2 as provided above. 
A) slijeda iznijetog u SEQ ID NO 2 HR P20171736 T1 B) slijeda koji je najmanje 80% identičan slijedu u SEQ ID NO 2.
The method according to claim 1, wherein the disease or disorder is prostate cancer. 
Spoj za uporabu prema zahtjevu 1, naznačen time, da bolest ili poremećaj je rak dojke.
D = standard resin of the liquid type. 
D = standardna smola tekućeg tipa.
as described above, for attaching to a dispensing tap 4. 
kao što je gore opisano, za spajanje na pipac 4 za točenje.
Use according to claim 17, wherein the buccal diseases are selected from: herpes simplex complex 1 (HSV-1), genital herpes (HSV-2), oral mucositis, oral Candidiasis, oral hairy leukoplakia, oral ulcers, salivary gland disturbance, altered oral flora (decreased bacterial flora), taste dysfunction, periodontitis, xerostomia, gastrointestinal mucositis causing secondary changes in oral status including inflammation, hygiene and dietary intact and oral pain. 
Primjena prema patentnom zahtjevu 17, naznačena time što su bolesti usne šupljine izabrane iz grupe koju čine: herpes simpleks kompleks 1 (HSYV-1), genitalni herpes (HSV-2), oralni mukozitis, oralna kandidijaza, oralna dlakava leukoplakija, oralni čirevi, poremećaji pljuvačnih žlijezda, promjenjena oralna flora (smanjena bakterijska flora), poremećaj ukusa, periodontitis, kserostomija, gastrointestinalni mukozitis koji uzrokuje sekundarno promjene u oralnom statusu koji obuhvaća nepromjenjenu inflamaciju, higijenu i ishranu, kao i oralni bol.
After a recovery period, implanted mice (for EEG recording) were injected with kainic acid. 
Nakon perioda oporavka, miševima je s implantatima (za bilježenje EEG-a) injektirana kainska kiselina.
For the present invention, the Stiff & Davis Saturation Index can also be kept under 2 by pH adjustment, the addition of antiscalants, or a water softening process. 
Postupak za obradu vode uz nizak trošak, prema zahtjevu 1, naznačen time što se Langelierov indeks zasićenja i Stilf & Davisov indeks zasićenja drži ispod 2 postupkom odabranim od podešavanja pH, dodavanja antiskalanta, ili postupkom omekšavanja vode.
removing the solvent or detergent forming a sterol membrane on the surface 
uklanjanja otapala ili deterdženta čime se formira sterolna membrana na površini
CHO-K1 cell culture medium: 
Medij kulture CHO-K1 stanica:
an aluminum or aluminum alloy powder incorporated into the binder, wherein the aluminum or the aluminum alloy powder and the binder are contained as a one-part composition, the aluminum or the aluminum alloy powder and the binder contained in a predetermined weight ratio; wherein the aluminum or aluminum alloy powder in the slurry is between 35-45 weight percent (wt%) based on the total weight of the slurry and the silicate to aluminum is contained in a ratio of 0.22:1 to 0.37:1 by weight. 
Vodeni gusti sastav za proizvodnju obloge na supstratu, obuhvaća: vezivo koje sadrži vodenu otopinu kalijevog silikata obogaćenu litijem, vezivo je karakterizirano odsustvom kroma; i aluminij ili prah aluminijeve slitine ugrađen u vezivo, pri čemu su aluminij ili prah aluminijeve slitine i vezivo sadržani kao jednodijelmi sastav, aluminij ili prah aluminijeve slitine i vezivo sadržani su u predodređenom masenom udjelu; pri čemu je maseni udio aluminija ili praha aluminijeve slitine u gustoj smjesi između 34-45 (wt%) na temelju ukupne mase guste otopine i silikat je u odnosu na aluminij sadržan u omjeru mase od 0.22:1 do 0.37:1.
The method of claim 1, wherein the FTI is lonafarnib. The method of claim 1, wherein the FTI is BMS-214662. The method of claim 1, wherein the FTI is administered at a dose of 1-1000 mg/kg body weight. 
Spoj za uporabu u skladu s patentnim zahtjevom 1, pri čemu je tipifarnib primijenjen u dozi od 1-1000 mg/kg tjelesne mase ili pri čemu je tipifarnib primijenjen u dozi od 600 mg dva puta dnevno ili u dozi od 900 mg dva puta dnevno.
In particular, the invention contemplates the use of either a carboxylic acid of generalized formula R7COOH, a carboxylic acid halide such as an acid chloride of generalized formula R7COCl, or a carboxyl anhydride of generalized formula R7COOCOR7. 
Ovaj izum naročito promatra upotrebu bilo karboksilne kiseline opće formule R;COOH, halogenida karboksilne kiseline kao što je kiselinski klorid opće formule R;COOCI, ili karboksilnog anhidrida opće formule R;-COOCOR;.
the mobile station apparatus (200) calculates an amount of resources for the reception quality information based on the resource allocation information, wherein the amount of the resources for the reception quality information calculated based on the resource allocation information does not exceed a predefined amount, and 
Uređaj mobilne stanice (200) prema zahtjevu 5, naznačen time da se količina resursa za ACK ili NACK koji se istovremeno odašilju sa odlaznim podacima izračunava tako da količina resursa ne prelazi prethodno određenu količinu.
The antibody, immunoconjugate, pharmaceutical composition, bispecific or multispecific molecule or expression vector for use according to any one of claims 24 to 29, wherein the method comprises administration of one or more further therapeutic agents to the subject. 
Antitijelo, imunokonjugat, bispecifična ili multispecifična molekula, farmaceutski pripravak ili vektor ekspresije za primjenu prema bilo kojem zahtjevu od 18 do 21, naznačen time, što se postupak sastoji od primjene jednog ili više dodatnih terapeutskih sredstava kod bolesnika.
The solid fractions were product and were combined. 
Krute frakcije čine produkt i međusobno se spoje.
A method for formulating minicells of the composition of claim 1, comprising co-incubating in a buffer (A) a plurality of intact, bacterially-derived minicells with (B) plasmid-free, regulatory RNA, thereby obtaining minicells that contain said regulatory RNA, wherein said regulatory RNA is selected from the group consisting of siRNA, miRNA and shRNA. 
Postupak oblikovanja mini-stanica pripravka prema zahtjevu 1, obuhvaća u puferu zajedničku inkubaciju (A) mnoštva intaktnih, bakterijski dobivenih mini-stanica s (B) regulatornom RNA bez plazmida, pri čemu se dobiju mini-stanice koje sadrže tu regulatornu RNA, gdje se ta regulatorna RNA izabire iz grupe koja obuhvaća siRNA, MIRNA i shRNA.
A product according to any of claim 1 to 6 in a form suitable for administration by inhalation via a medicament dispenser selected from a reservoir dry powder inhaler, a unit-dose dry powder inhaler, a pre-metered multi-dose dry powder inhaler, a nasal inhaler or a pressurized metered dose inhaler. A product according to claim 7, wherein Compound (I) and Compound (II) are presented in separate dry powder compositions or an admixed dry powder composition. 
Proizvod namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što je u obliku pogodnom za primjenu inhaliranjem putem dozatora lijeka koji se bira između inhalatora sa spremnikom sa suhim prahom, jednodoznog inhalatora sa suhim prahom, višedoznog inhalatora za prethodno odmjerene doze sa suhim prahom, nazalnog inhalatora ili inhalatora pod tlakom za odmjerene doze.
The molecule for use of claim 2, wherein the amino acid sequence which alters the solubility or affinity comprises an immunoglobulin. 
Molekula za uporabu iz patentnog zahtjeva 2, pri čemu slijed aminokiselina koji mijenja topljivost ili afinitet obuhvaća imunoglobulin.
A process of claim 1, wherein the process is performed as a one-pot process and/or without isolation of a compound of formula IV. 
se postupak izvodi kao postupak u jednom reaktoru i/ili bez izoliranja spoja formule IV i/ili;
where R1-R13 are as defined herein, and L is a leaving group such as e.g. halogen, mesylate or tosylate; whereupon the compound of formula IA is isolated as the free base or a salt such as a pharmaceutically acceptable acid addition salt thereof. Method 2 (for compounds of formula IA) Reduction of an amide derivative of formula IV: 
(in (TD u kojoj su R'-R'? kako je to ovdje definirano a L je napuštajuća grupa kao stoje to npr. halogen, mesilat ili tosilat; nakon čega se spoj formule IA izolira kao slobodna baza ili sol kao što je to farmaceutski prihvatljiva njegova kisela dodatna sol. Metoda 2 (za spojeve formule IA).
SEQ ID NO: 9 sets forth a nucleotide sequence encoding a short hairpin RNA TLR-3 agonist (g1). 
Vektor za primjenu prema zahtjevu 1, naznačen time, što je heterologna dsRNK kratka RNK u obliku ukosnice (ShRNA).
In another embodiment, Compounds of the Invention are compounds of any of Formulae I-IX, XII, or XIII, and the pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R11 is —NR1aR2a and R1a and R2a taken together with the nitrogen atom to which they are attached form a 5- or 6-membered optionally substituted heterocyclo. 
Tvar iz bilo kojeg od patentnih zahtjeva 1-5, gdje R* i R* uzeti zajedno s atomom dušika za koji su pričvršćeni tvore 5- ili 6- člani opcionalno supstituirani heterocikl, ili njegovu farmaceutski prihvatljivu sol i, gdje je navedeni opcionalno supstituirani 5- ili 6- člani heterocikl poželjno odabran iz grupe koja se sastoji od: i
at least one needle (13) in the lumen adapted to assume a deployed position and a retracted position; 
Renalni denervacijski kateter prema zahtjevu 1, pri čemu se najmanje jedna igla (113) prostire prema van u radijalnom smjeru.
determining the blood GLP-1 level in a blood or a plasma sample obtained from a mammal, the mammal having been administered with the test compound in the presence of which less of the complex is formed in step (c), wherein the ability of the test compound to increase a blood GLP-1 level in the blood or the plasma sample obtained from the mammal identifies the test compound as a GLP-1 secretagogue. 
(d) određivanja nivoa GLP-1 u krvi u biološkom uzorku dobivenom iz sisavca, pri čemu je navedenom sisavcu bio primjenjen spoj u prisutnosti kojeg se formira manje navedenog kompleksa iz koraka (c); pri čemu je sposobnost test spoja da poveća nivo GLP-I u krvi u sisavcu nadalje indikativna da je test spoj GLP-I sekretogog. 2.
Such caps can be easily lost if they are not retained on the inhaler in some manner. 
Takvi se zatvarači lako mogu izgubiti ako na neki način nisu vezani za inhalator.
The ASM for use of claim 17, wherein said missense mutation is L302P, H421Y or R496L. 
KSM za uporabu u skladu s patentnim zahtjevom 17, pri čemu je navedena mutacija L302P, H421Y ili R496L.
Paragraph 12. The recombinant virus of paragraph 11, wherein the virus selectively expresses E1a-12S. 
Predmetni sadržaj prema zahtjevu 11, gdje rekombinantni adenovirus selektivno eksprimira E1a-125 ili Ela13S.
a granule comprising a therapeutic compound in an intimate mixture with at least one pharmaceutically acceptable excipient, wherein said therapeutic compound is a pyrimidylaminobenzamide compound of formula I: 
granule koje sadrže terapijski spoj u bliskoj smjesi s barem jednom farmaceutski prikladnom pomoćnom tvari, gdje je taj terapijski spoj
a modulator (712,713) configured to perform an inverse fast fourier transform, IFFT, and a guard interval insertion on a broadcast signal including the signal frame, 
modulator (712, 713) konfiguriran za provođenje inverzne brze fourier transformacije, IFFT, i umetanje intervala čuvara u okvir signala za kreiranje signala emitiranja; i sredstvo prijenosa konfigurirano za prijenos emitiranog signala;
6; and/or in its light chain constant region the amino acid sequence shown in SEQ ID NO. 
6; ifili u svom konstantnom području lakog lanca aminokiselinski slijed prikazan u SEQ ID NO.
or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein: 
Spoj s formulom: ili njegova farmaceutski prihvatljiva sol ili stereoizomer.
is selected from the group consisting of isopropenyl, Z-2-propen-3-yl and (+)-vinyl; 
Ri R? su svaki klor; R* je izabran iz grupe koja se sastoji od izopropenil.
A compound of any one of claims 1 to 24 for use in treating a disease mediated by a kinase selected from c-kit, PDGFRa, and PDGFRB, wherein the disease is a respiratory disease, an inflammatory disorder, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), an autoimmune disorder, a metabolic disease, a fibrosis disease, a dermatological disease, pulmonary arterial hypertension (PAH) or primary pulmonary hypertension (PPH). 
Spoj prema bilo kojem od zahtjeva 1 do 24, naznačen time, što je za uporabu u liječenju bolesti posredovane s kinazom koja je odabrana od c-kit, PDGFRa, i PDGFRB, pri čemu bolest je respiratorna bolest, upalni poremećaj, sindrom iritabilnog crijeva (IBS), upalna bolest crijeva (IBD), autoimuni poremećaj, metabolička bolest, fibrozna bolest, dermatološka bolest, plućna arterijska hipertenzija (PAH) ili primarna plućna hipertenzija (PPH).
Another embodiment is a compound of the formula: 
Datum objave europske prijave patenta:
reacting such compound with a chiral reagent to form a chiral center at the tetrahydronaphthalene moiety carbon previously bound to the oxo group. 
(i) reakcije takvog spoja s kiralnim reagensom kako bi se dobilo kiralni centar na ugljiku u tetrahidronaftalenskom ostatku, prethodno vezan na skupinu okso.
The DNA molecule of claim 12, wherein said IgG1 is encoded by a sequence shown in SEQ ID NO: 27 or SEQ, ID NO: 31 or SEQ ID NO: 23. 
DNK-molekula prema zahtjevu 12, naznačena time, da navedeni IgG1 se kodira pomoću sekvence prikazane u SEQ ID NO:27 ili SEQ ID NO:31 ili SEQ ID NO:23.
The method according to claim 1, wherein the xerostomia is associated with head and neck cancer. 
Betanekol za uporabu prema zahtjevu 1, pri čemu je kserostomija povezana s rakom glave i vrata.
The method according to claim 1 or 2, wherein the X-ray powder diffraction pattern further comprises peaks at 17.61, 17.77 and 27.66 degrees 2Θ (±0.1 degrees 2Θ), wherein said X-ray powder diffraction pattern is made using CuKa1 radiation. 
Postupak prema zahtjevu 1 ili 2, naznačen time, da uzorak difrakcije praha X-zraka nadalje obuhvaća vršne vrijednosti na 17,61, 17,77 i 27,66 stupnjeva 2θ (± 0,1 stupanj 2θ), pri čemu se navedeni uzorak difrakcije praha X-zraka dobiva uporabom CuKa1-radijacije.
one or more therapeutically active agent selected from statins, fibrates, bile-acid binding resins and nicotinic acid; and 
jedno ili više terapijski aktivnih sredstava, koja se bira između statina, fibrata, smola koje vežu žučne kiseline i nikotinsku kiselinu; i
Preparative HPLC of the three components (Column: 2 x Lichrospher Si60, 5 µm, 250 x 21.20 mm, mobile phase: hexane: isopropanol (97:3), UV 254 nm; flow: 10 ml min-1) at 300 mg loading followed by concentration of the fractions of interest under vacuum gave the pure Mosher's ester derivatives Peak 1 (3.89 g, 46.5%) Peak 2 (2.78 g, 33%) 
Preparativna HPLC tri sastojka (kolona: 2 x Lichrospher S160, 5 um, 250 x 21.20 mm, mobilna faza: heksan: izopropanol (97:3), UV 254 nm; protok: 10 ml min") uz punjenje od 300 mg i neposredno nakon koje slijedi koncentriranje poželjnih frakcija uz vakuum, daje čiste derivate Mosher-ovog estera. Peak 1 (3.89 g, 46.5%) Peak 2 (2.78 g, 33%)
Use according to claim 26, wherein said neurodegenerative disorders are selected from the group consisting of Alzheimer's disease, Huntington's chorea, multiple sclerosis, amyotrophic lateral sclerosis, Creutzfeld-Jakob's disease, Parkinson's disease, encephalopathies induced by AIDS or infection by rubella viruses, herpes viruses, borrelia or unknown pathogens, trauma-induced neurodegenerations, neuronal hyperexcitation states such as in medicament withdrawal or intoxication, and neurodegenerative diseases of the peripheral nervous system such as polyneuropathies and polyneuritides. 
Primjena prema patentnom zahtjevu 22, naznačena time što su navedeni neurodegenerativni poremećaji izabrani iz grupe koju čine Alzheimer-ova bolest, Huntington-ova horea, multipla skleroza, amiotrofna lateralna skleroza, Creutzfeld-Jakob-ova bolest, Parkinson-ova bolest, encefalopatije izazvane SIDA-om ili infekcijom virusima rubeole, herpes virusima, borelijom ili nepoznatim patogenima, neurodegeneracije izazvane traumom, stanja živčane hiperekscitacije kao što je apstinencijalni sindrom kod zlouporabe lijekova ili intoksikacija lijekovima, i neurodegenerativne bolesti perifernog žičanog sustava kao što su polineuropatije i polineuritisi.
Process according to claim 4 characterized in that the compound obtained is enantiomerically pure (R)-pirlindole hydrobromide salt. 
Proces u skladu sa patentnim zahtjevom 4 naznačen time da dobiveni spoj je enantiomerno čista (R)-pirlindol hidrobromid sol.
is C1-C8-alkyl optionally substituted by OH, halogen C6-C10-aryl optionally substituted by OH, SO2R10, SC1-C8-alkyl, CN, halogen, O-C7-C14-aralkyl, or O-C1-C8-alkyl, a C3-C15-carbocyclic group optionally substituted by O-C7-C14 aralkyl, C3-C15-carbocyclic group, O-C1-C8-alkyl, C2-C8-alkenyl, C2-C8-alkynyl or C1-C8-alkyl, O-C1-C8-alkyl, -SO2-C1-C8-alkyl, a 3- to 12-membered heterocyclic group containing from 1-4 ring nitrogen atoms and optionally containing from 1-4 other heteroatoms selected from the group consisting of oxygen and sulfur, that group being optionally substituted by 3- to 12-membered heterocyclic group containing from 1-4 ring nitrogen atoms and optionally containing from 1-4 other heteroatoms selected from the group consisting of oxygen and sulfur, C7-C14-aralkyl, or C6-C14-aryl optionally substituted by O-C7-C14-aralkyl, or 
je C1-C8-alkil opcijski supstituiran sa OH, halogen, C6-C10-aril opcijski supstituiran sa OH, SC1-C8-alkilom, CN, halogenom, O-C7-C14-aralkilom, ili O-C1-C8-alkilom, C3-C15-karbociklička skupina opcijski supstituirana sa O-C7-C14 aralkilom, C3-C15-karbocikličkom skupinom, O-C1-C8-alkilom, C2-C8-alkenilom, C2-C8-alkinilom ili C1-C8-alkilom, O-C1-C8-alkil, -SO2-C1-C8-alkil, 3- do12-člana heterociklička skupina koja sadrži 1 do 4 prstena dušikovih atoma i opcijski sadrži od 1 do 4 drugih heteroatoma odabranih iz skupine koja obuhvaća kisik i sumpor, a ta skupina se opcijski supstituira sa 3- do 12-članom heterocikličkom skupinom koja sadrži od 1 do 4 prstena dušikovih atoma i opcijski sadrži od 1 do 4 drugih heteroatoma odabranih iz skupine koja obuhvaća kisik i sumpor, C7-C14-aralkil, ili C6-C14-aril opcijski supstituiran sa O-C7-C14-aralkilom, ili
Formulation according to claims 6 or 7, wherein it is a citrate buffered solution and the pH of the formulation is adjusted to from 6.0 to 7.5. 
Formulacija u skladu s patentnim zahtjevima 5 ili 6, naznačena time što je otopina puferirana citratom, a pH formulacije je podešen na 6,0 do 7,5.
Use of a compound according to any one of claims 1-18 for the manufacture of a pharmaceutical composition for the treatment of a disorder or disease that is responsive to an increased ion flow in a potassium channel, said disorder or disease preferably being a disorder or disease of the central nervous system. 
Primjena spojeva prema bilo kojem od patentnih zahtjeva 1-18, naznačena time što se koristi za proizvodnju farmaceutske kompozicije za liječenje poremećaja ili bolesti koja je osjetljiva na povećani protok iona u kalijevom kanalu, pri čemu je nevedeni poremećaj ili bolest poželjno poremećaj ili bolest središnjeg živčanog sustava.
the particle contrast agent composition further comprises sodium chloride and a phosphate buffered saline including at least sodium phosphate dibasic and potassium phosphate monobasic. 
Postupak prema zahtjevu 12, naznačen time da: pripravak kontrastnog sredstva za čestice dodatno sadrži natrijev klorid i fosfatno puferiranu fiziološku otopinu koja sadrži barem dvobazni natrijev fosfat i monobazni kalijev fosfat.
The peptide according to any of Claims 1 to 3, wherein said peptide is part of a fusion protein, in particular comprising N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii). 
Peptid u skladu s patentnim zahtjevom 1 ili 2, pri čemu je navedeni peptid dio fuzijskog proteina. Peptid u skladu s patentnim zahtjevom 3, pri čemu navedeni fuzionirani protein sadrži N-terminalne aminokiseline HLA-DR invarijantnog lanca vezanog za antigene (Ii).